Coherus Bioscience News Today

The latest analyst coverage could presage a bad day for Coherus BioSciences, Inc. ( NASDAQ:CHRS ), with the analysts...

By Ben Glickman Coherus BioSciences' finance chief McDavid Stilwell has resigned from the company to pursue other opportunities. The Redwood City,...

Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has begun

Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher Monday after the company announced the FDA-approval of Loqtorzi in all lines of treatment for

A survey of gastroenterologists, dermatologists, and rheumatologists found Amjevita had the most recognition, followed by Cyltezo, the only interchangeable biosimilar on the US market.

Newark, New Castle, USA, June 20, 2023 (GLOBE NEWSWIRE) -- According to the most recent study by Growth Plus Reports, the chemotherapy devices market was valued at US$ 11.84 billion and is expected to rise at a revenue

The ASCO annual meeting just got underway Friday in Chicago, kicking off the oncology community's largest medical meeting of the year. Read more here.

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.

MeiraGTx (NASDAQ:MGTX – Get Rating) and Coherus BioSciences (NASDAQ:CHRS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations. Earnings & Valuation This table compares MeiraGTx and Coherus BioSciences’ […]

Sutro Biopharma (NASDAQ:STRO – Get Rating) and Coherus BioSciences (NASDAQ:CHRS – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership. Analyst Recommendations This is a summary of recent ratings […]